The role of high power ultrasound in restoring blood flow for patients presenting with a major heart attack.

Not Applicable

Recruiting

• Conditions: Ischaemic Heart Disease; ST Elevation Myocardial Infarction; Coronary Microvascular Dysfunction; Microvascular Obstruction; Heart Failure; Cardiovascular - Coronary heart disease; Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12620000807954
• Lead Sponsor: niversity of Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-08-11
• Last Update Posted: 27 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

Chest Pain with ST segment elevation >0.1 mV in two contiguous leads, or ST segment depression >0.2mV in two contiguous leads V1-V3 (consistent with a posterior STEMI)
- Eligible for emergent PCI/antithrombotic/antiplatelet therapy.
- Adequate apical and/or parasternal images by echocardiography.
- No contraindications or hypersensitivities to ultrasound contrast agents.

Exclusion Criteria

- Unable to provide written consent to participate in the trial
- Chest pain lasting >6 hours
- Cardiogenic shock
- Fibrinolytic therapy prior to arrival in the emergency department
- Life expectancy of less than six months from any other co-morbidity or terminally ill
- Prior ST-segment elevation myocardial infarction (STEMI)
- Known or suspected hypersensitivity to perflutren, the contrast agent used for the study
- Known cardiomyopathy
- Known severe valvular heart disease
- Known bleeding diathesis or contraindication to glycoprotein 2b/3a inhibitors, anticoagulants, or aspirin
- Known large right to left intra-cardiac shunts
- Pregnancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Infarct Size will be assessed on Cardiac Magnetic Resonance (CMR) Imaging as the volume of late Gadolinium enhancement (expressed as % of total myocardium)[ At day 4 +/-2 (Primary endpoint) and 6 months post intervention]